EXEL
Exelixis Inc
NASDAQ: EXEL · HEALTHCARE · BIOTECHNOLOGY
$53.13
-0.69% today
Updated 2026-06-12
Market cap
$13.35B
P/E ratio
17.59
P/S ratio
5.62x
EPS (TTM)
$3.02
Dividend yield
—
52W range
$34 – $54
Volume
2.6M
Exelixis Inc (EXEL) Insider transactions
Net insider activity
Net selling (908,883 shares)
Buy transactions
34
Sell transactions
66
All transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-01 | WYSZOMIERSKI, JACK L | Director | Sale | 3,925 | $50.55 | $198408.75 |
| 2026-06-01 | ECKHARDT, SUE GAIL | Director | Sale | 9,812 | $50.14 | $491973.68 |
| 2026-05-27 | WYSZOMIERSKI, JACK L | Director | Buy | 8,367 | — | — |
| 2026-05-27 | SMITH, JULIE | Director | Buy | 8,367 | — | — |
| 2026-05-27 | POSTE, GEORGE | Director | Buy | 8,367 | — | — |
| 2026-05-27 | PAPADOPOULOS, STELIOS | Director | Buy | 8,367 | — | — |
| 2026-05-27 | OLIVER, BOB | Director | Buy | 8,367 | — | — |
| 2026-05-27 | JOHNSON, DAVID EDWARD | Director | Buy | 19,133 | — | — |
| 2026-05-27 | HEYMAN, TOMAS J. | Director | Buy | 8,367 | — | — |
| 2026-05-27 | FREIRE, MARIA C | Director | Buy | 8,367 | — | — |
| 2026-05-27 | ECKHARDT, SUE GAIL | Director | Buy | 8,367 | — | — |
| 2026-05-27 | BECKERLE, MARY C | Director | Buy | 8,367 | — | — |
| 2026-05-26 | AFTAB, DANA | EVP, Research and Development | Sale | 43,451 | $50.35 | $2.19M |
| 2026-05-20 | HALEY, PATRICK J. | EVP, Commercial | Sale | 32,110 | $49.81 | $1.60M |
| 2026-05-18 | SENNER, CHRISTOPHER J. | EVP and CFO | Sale | 34,901 | $50.00 | $1.75M |
| 2026-05-18 | MORRISSEY, MICHAEL | Director, President and CEO | Sale | 124,047 | — | — |
| 2026-05-18 | HEFTI, BRENDA | SVP and General Counsel | Sale | 6,625 | $50.21 | $332641.25 |
| 2026-05-15 | SENNER, CHRISTOPHER J. | EVP and CFO | Sale | 40,892 | $51.10 | $2.09M |
| 2026-05-15 | MORRISSEY, MICHAEL | Director, President and CEO | Sale | 128,497 | $51.10 | $6.57M |
| 2026-05-15 | HEFTI, BRENDA | SVP and General Counsel | Sale | 6,411 | $51.10 | $327602.10 |
| 2026-05-15 | HALEY, PATRICK J. | EVP, Commercial | Sale | 33,265 | $51.10 | $1.70M |
| 2026-05-15 | AFTAB, DANA | EVP, Research and Development | Sale | 30,578 | $51.10 | $1.56M |
| 2026-05-07 | POSTE, GEORGE | Director | Sale | 60,000 | $45.71 | $2.74M |
| 2026-05-07 | FREIRE, MARIA C | Director | Sale | 20,634 | — | — |
| 2026-05-07 | FREIRE, MARIA C | Director | Buy | 20,634 | $19.77 | $407934.18 |
| 2026-05-07 | BECKERLE, MARY C | Director | Sale | 3,856 | — | — |
| 2026-05-07 | BECKERLE, MARY C | Director | Sale | 7,712 | $48.45 | $373646.40 |
| 2026-05-07 | BECKERLE, MARY C | Director | Buy | 3,856 | $23.24 | $89613.44 |
| 2026-05-06 | MORRISSEY, MICHAEL | Director, President and CEO | Sale | 109,676 | — | — |
| 2026-02-26 | SENNER, CHRISTOPHER J. | EVP and CFO | Buy | 52,018 | — | — |
| 2026-02-26 | MORRISSEY, MICHAEL | Director, President and CEO | Buy | 160,437 | — | — |
| 2026-02-26 | HEFTI, BRENDA | SVP and General Counsel | Buy | 23,119 | — | — |
| 2026-02-26 | HALEY, PATRICK J. | EVP, Commercial | Buy | 40,459 | — | — |
| 2026-02-26 | AFTAB, DANA | EVP, Research and Development | Buy | 52,018 | — | — |
| 2026-02-24 | MORRISSEY, MICHAEL | Director, President and CEO | Sale | 100,278 | — | — |
| 2026-02-24 | AFTAB, DANA | EVP, Research and Development | Sale | 47,918 | $44.50 | $2.13M |
| 2026-02-19 | AFTAB, DANA | EVP, Research and Development | Sale | 29,873 | $44.35 | $1.32M |
| 2026-02-18 | WYSZOMIERSKI, JACK L | Director | Sale | 20,634 | — | — |
| 2026-02-18 | WYSZOMIERSKI, JACK L | Director | Sale | 99,574 | $44.01 | $4.38M |
| 2026-02-18 | WYSZOMIERSKI, JACK L | Director | Buy | 20,634 | $19.77 | $407934.18 |
| 2026-02-18 | SMITH, JULIE | Director | Sale | 44,087 | — | — |
| 2026-02-18 | SMITH, JULIE | Director | Sale | 20,030 | — | — |
| 2026-02-18 | SMITH, JULIE | Director | Sale | 44,087 | $44.50 | $1.96M |
| 2026-02-18 | SMITH, JULIE | Director | Sale | 20,030 | $44.30 | $887329.00 |
| 2026-02-18 | MORRISSEY, MICHAEL | Director, President and CEO | Buy | 125,094 | — | — |
| 2026-02-18 | HEFTI, BRENDA | SVP and General Counsel | Sale | 18,669 | $44.01 | $821622.69 |
| 2026-02-17 | SMITH, JULIE | Director | Sale | 42,422 | — | — |
| 2026-02-17 | SMITH, JULIE | Director | Sale | 42,422 | $43.33 | $1.84M |
| 2026-02-17 | SENNER, CHRISTOPHER J. | EVP and CFO | Sale | 30,617 | $43.67 | $1.34M |
| 2026-02-17 | MORRISSEY, MICHAEL | Director, President and CEO | Buy | 250,736 | — | — |
| 2026-02-17 | HALEY, PATRICK J. | EVP, Commercial | Sale | 64,778 | $43.50 | $2.82M |
| 2026-02-17 | HALEY, PATRICK J. | EVP, Commercial | Sale | 3,036 | $43.84 | $133098.24 |
| 2026-02-15 | SENNER, CHRISTOPHER J. | EVP and CFO | Sale | 35,870 | $43.92 | $1.58M |
| 2026-02-15 | MORRISSEY, MICHAEL | Director, President and CEO | Sale | 120,390 | $43.92 | $5.29M |
| 2026-02-15 | HEFTI, BRENDA | SVP and General Counsel | Sale | 5,430 | $43.92 | $238485.60 |
| 2026-02-15 | HALEY, PATRICK J. | EVP, Commercial | Sale | 31,483 | $43.92 | $1.38M |
| 2026-02-15 | AFTAB, DANA | EVP, Research and Development | Sale | 26,485 | $43.92 | $1.16M |
| 2026-02-15 | AFTAB, DANA | EVP, Research and Development | Sale | 12,720 | $43.92 | $558662.40 |
| 2026-02-13 | SENNER, CHRISTOPHER J. | EVP and CFO | Sale | 34,278 | $43.00 | $1.47M |
| 2026-02-13 | OLIVER, BOB | Director | Sale | 9,088 | — | — |
| 2026-02-13 | OLIVER, BOB | Director | Sale | 21,162 | $43.90 | $929011.80 |
| 2026-02-13 | OLIVER, BOB | Director | Sale | 9,088 | $43.61 | $396327.68 |
| 2026-02-13 | MORRISSEY, MICHAEL | Director, President and CEO | Sale | 494,700 | — | — |
| 2026-02-13 | MORRISSEY, MICHAEL | Director, President and CEO | Buy | 494,700 | $21.31 | $10.54M |
| 2026-02-13 | MORRISSEY, MICHAEL | Director, President and CEO | Sale | 369,606 | $43.92 | $16.23M |
| 2026-02-13 | ECKHARDT, SUE GAIL | Director | Sale | 3,856 | $43.79 | $168854.24 |
| 2026-01-15 | SENNER, CHRISTOPHER J. | EVP and CFO | Buy | 149,474 | — | — |
| 2026-01-15 | SENNER, CHRISTOPHER J. | EVP and CFO | Sale | 40,459 | $45.23 | $1.83M |
| 2026-01-15 | MORRISSEY, MICHAEL | Director, President and CEO | Buy | 548,073 | — | — |
| 2026-01-15 | MORRISSEY, MICHAEL | Director, President and CEO | Sale | 139,524 | $45.23 | $6.31M |
| 2026-01-15 | HALEY, PATRICK J. | EVP, Commercial | Buy | 139,508 | — | — |
| 2026-01-15 | HALEY, PATRICK J. | EVP, Commercial | Sale | 32,332 | $45.23 | $1.46M |
| 2026-01-15 | AFTAB, DANA | EVP, Research and Development | Buy | 119,578 | — | — |
| 2026-01-15 | AFTAB, DANA | EVP, Research and Development | Sale | 27,254 | $45.23 | $1.23M |
| 2025-12-03 | HEFTI, BRENDA | SVP and General Counsel | Buy | 30,170 | — | — |
| 2025-11-25 | JOHNSON, DAVID EDWARD | Director | Buy | 27,532 | $43.12 | $1.19M |
| 2025-11-21 | HALEY, PATRICK J. | EVP, Commercial | Sale | 28,043 | $42.58 | $1.19M |
| 2025-11-21 | AFTAB, DANA | EVP, Research and Development | Sale | 24,000 | — | — |
| 2025-11-20 | HALEY, PATRICK J. | EVP, Commercial | Sale | 23,539 | $41.93 | $986990.27 |
| 2025-11-20 | HALEY, PATRICK J. | EVP, Commercial | Sale | 10,648 | $41.77 | $444766.96 |
| 2025-11-20 | HALEY, PATRICK J. | EVP, Commercial | Sale | 10,000 | $42.11 | $421100.00 |
| 2025-11-17 | OLIVER, BOB | Director | Sale | 1,044 | — | — |
| 2025-11-12 | PAPADOPOULOS, STELIOS | Director | Sale | 100,000 | $43.55 | $4.36M |
| 2025-11-12 | MORRISSEY, MICHAEL | Director, President and CEO | Sale | 101,548 | — | — |
| 2025-11-12 | MORRISSEY, MICHAEL | Director, President and CEO | Sale | 80,000 | — | — |
| 2025-11-11 | MORRISSEY, MICHAEL | Director, President and CEO | Sale | 160,000 | — | — |
| 2025-11-11 | BECKERLE, MARY C | Director | Sale | 5,784 | — | — |
| 2025-11-11 | BECKERLE, MARY C | Director | Sale | 18,838 | $41.90 | $789312.20 |
| 2025-11-11 | BECKERLE, MARY C | Director | Sale | 5,784 | $42.03 | $243101.52 |
| 2025-11-11 | AFTAB, DANA | EVP, Research and Development | Sale | 48,383 | $42.50 | $2.06M |
| 2025-10-08 | AFTAB, DANA | EVP, Research & Development | Buy | 50,673 | — | — |
| 2025-06-03 | WYSZOMIERSKI, JACK L | Director | Sale | 7,535 | $43.09 | $324683.15 |
| 2025-06-02 | ECKHARDT, SUE GAIL | Director | Sale | 18,834 | $42.74 | $804965.16 |
| 2025-06-02 | ECKHARDT, SUE GAIL | Director | Sale | 4 | $43.67 | $174.68 |
| 2025-05-29 | WYSZOMIERSKI, JACK L | Director | Buy | 9,812 | — | — |
| 2025-05-29 | SMITH, JULIE | Director | Buy | 9,812 | — | — |
| 2025-05-29 | POSTE, GEORGE | Director | Buy | 9,812 | — | — |
| 2025-05-29 | PAPADOPOULOS, STELIOS | Director | Buy | 9,812 | — | — |
| 2025-05-29 | OLIVER, BOB | Director | Buy | 9,812 | — | — |
| 2025-05-29 | JOHNSON, DAVID EDWARD | Director | Buy | 21,464 | — | — |
Frequently asked questions
Are EXEL insiders buying or selling?
Over the transactions on record, EXEL insiders have been net sellers, with about $91.42M in stock sold across 66 sales, against 5 open-market purchases.
Does insider selling at EXEL mean the stock will fall?
Not by itself. Most executive selling is pre-scheduled through 10b5-1 plans filed months in advance, and insiders sell for diversification, taxes, and liquidity far more often than out of any view on the price. Insider buying is the stronger signal, especially when several insiders buy around the same time, because there is usually only one reason to put personal cash into the stock.
Which EXEL insiders are selling the most?
Recent selling is concentrated in a few names. MORRISSEY, MICHAEL accounts for the largest share on record, with about $34.40M sold. Selling by one or two individuals matters less than broad selling across the whole leadership team, which is the pattern worth watching.